ArticlePathogens (Basel, Switzerland)2021
Correlation of
Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Development of a point-of-care dual one-step recombinase-aided PCR assay for rapid identification ofFrontiers in microbiology · 2026Article
- Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis.Frontiers in cellular and infection microbiology · 2026Article
- Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-ResistantMicroorganisms · 2025Article
- Identification and quantification ofJournal of clinical microbiology · 2025Article
- Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.PloS one · 2025Article
- Whole-genome sequencing-based analyses of drug-resistant Mycobacterium tuberculosis from Taiwan.Scientific reports · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Fluoroquinolone (FQ) compounds-moxifloxacin (MOX), levofloxacin (LEV), and ofloxacin (OFL)-are used to treat multidrug-resistant tuberculosis (MDR-TB) globally. In this study, we investigated the correlation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.